medRxiv preprint doi: https://doi.org/10.1101/2020.12.16.20248300; this version posted February 12, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Systematic review reveals multiple sexually antagonistic 1

polymorphisms affecting human disease and complex 2

traits 3

- 4
- Jon Alexander Harper^{1*}, Tim Janicke^{2,3} and Edward H. Morrow⁴ 5
- * Corresponding author 6
- 7 ¹Evolution, Behaviour and Environment Group, School of Life Sciences, John Maynard Smith
- 8 Building, University of Sussex, Brighton, BN1 9QG, UK.
- 9 ²Centre d'Écologie Fonctionnelle et Évolutive, UMR 5175, CNRS, Université de Montpellier,
- 10 École Pratique des Hautes Études, Montpellier, France.
- 11 ³Applied Zoology, Technical University Dresden, Zellescher Weg 20b, 01062 Dresden,
- 12 Germany.
- ⁴Department of Environmental and Life Sciences, Karlstad University, 651 88, Karlstad, 13
- 14 Sweden.
- 15
- 16 Jon Alexander Harper ORCID: 0000-0002-1765-9990
- 17 Tim Janicke ORCID: 0000-0002-1453-6813
- 18 Edward H Morrow ORCID: 0000-0002-1853-7469
- 19
- 20
- 21 Short title: Systematic review of sexually antagonistic genes in human disease

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

22

Abstract 23

24 An evolutionary model for sex differences in disease risk posits that alleles conferring higher 25 risk in one sex may be protective in the other. These sexually antagonistic (SA) alleles are 26 predicted to be maintained at frequencies higher than expected under purifying selection 27 against unconditionally deleterious alleles, but there are apparently no examples in humans. 28 Discipline-specific terminology, rather than a genuine lack of such alleles, could explain this 29 disparity. We undertook a two-stage review of evidence for SA polymorphisms in humans using search terms from (i) evolutionary biology and (ii) biomedicine. While the first stage 30 returned no eligible studies, the second revealed 51 genes with sex-opposite effects, 22 31 32 increased disease risk or severity in one sex but protected the other. Those with net positive 33 effects occurred at higher frequencies. None were referred to as SA. Our review reveals 34 significant communication barriers to fields as a result of discipline-specific terminology.

35 148 words

Introduction 37

38 In species with separate sexes an evolutionary conflict at the level of individual genetic loci 39 can occur, where alleles that are favoured by selection in one sex are selected against in the 40 other (i.e intralocus sexual conflict, Parker, 1979). This sexually antagonistic (SA) form of selection is thought to be driven by differences in how the two sexes maximize their fitness 41 42 and concomitant unequal variances in reproductive success. Research into SA selection has expanded recently with the recognition that it feeds into several important evolutionary 43 processes. It is primarily thought to drive the evolution of sexual dimorphism and trait 44 45 diversification (Lande, 1980; Pennell et al., 2016; Rice, 1984), including sex-biased gene 46 expression (Ellegren and Parsch, 2007). As a potential driver of balancing selection, it has also been implicated in the maintenance of genetic variation (Connallon and Clark, 2013; Grieshop 47 48 and Arnqvist, 2018) that would otherwise be eroded by directional selection. Most recently, it has been suggested that genetic variation at SA loci could contribute to the occurrence of a 49 50 number of common human diseases (Morrow, 2015; Morrow and Connallon, 2013), which 51 also show considerable variation between the sexes in terms of their prevalence, severity and age of onset (Ober et al., 2008; Rigby and Kulathinal, 2015). 52

53 Despite the interest in sexual antagonism as an evolutionary force, determining the identity of SA loci remains a major challenge (Ruzicka et al., 2020). An early empirical 54 milestone in the field of sexual conflict was achieved by quantitative genetic studies 55 demonstrating that genomes in a laboratory adapted population of *Drosophila melanogaster* 56 harbour significant amounts of SA standing genetic variation (Chippindale et al., 2001; Rice, 57 1992). A number of other systems have shown similar results, albeit using different methods, 58 59 including invertebrates and vertebrates from both lab and wild populations (Bonduriansky 60 and Chenoweth, 2009; Foerster et al., 2007; Mills et al., 2011). With the advent of advanced 61 genomic tools, two model systems report specific examples of SA genetic loci: in Atlantic salmon (Salmo salar) the VGLL3 locus (Barson et al., 2015), and in D. melanogaster the DDT-62 R locus (Rostant et al., 2015), the Ala-278-Thr polymorphism in the mitochondrial genome 63 (Camus et al., 2015), and multiple candidate loci from a recent genome-wide association 64 study (Ruzicka et al., 2019). 65

66 Although humans have also been shown to experience SA selection for some 67 quantitative traits (Garver-Apgar et al., 2011; Stearns et al., 2012; Stulp et al., 2012), and there

68 are numerous reports of genetic loci with sex-specific effects (i.e. effects that differ in magnitude between the sexes) on multiple complex traits or disease phenotypes (Gilks et al., 69 70 2014; Winkler et al., 2015), there are apparently no clear examples of SA loci in humans, which 71 is inconsistent with theoretical expectations (Connallon and Clark, 2014). One potential 72 explanation is that sexual antagonism is a weak selective force in humans, with sexual 73 dimorphism being rather limited (Dixson, 2009; Short, 1979). This may indicate that 74 concordant selection pressures between the sexes have dominated our evolutionary history. But the recent quantitative genetic studies challenge this view (Stearns et al., 2012; Stulp et 75 76 al., 2012), and indeed theory predicts there is an inevitability to SA loci occurring in organisms 77 with separate sexes (Connallon and Clark, 2014; Parker et al., 1972). Thus, there is a clear 78 disparity between, on the one hand, theoretical expectations and quantitative genetic 79 evidence that SA selection does occur in humans, and on the other hand, a complete lack of 80 specific examples of SA loci. All this in the context of decades of research into how individual 81 genetic variants influence disease profiles.

82 An alternative explanation for the absence of documented SA loci in humans is that since biomedical science does not use the same terminology for SA effects that evolutionary 83 84 biology uses, there may in fact be examples that have been misclassified and therefore remain 85 hidden in the literature. For example, genetic loci with sex-specific effects are frequently 86 referred to as *sex-dependent* effects in the biomedical literature. Other terms are also used for related concepts, including sex-different effects. Furthermore, sex-opposite effects (i.e. a 87 88 positive effect in one sex and a negative in the other) could be SA effects if the phenotype in question is deleterious, as disease phenotypes often are, since they can influence an 89 90 individual's survival or reproductive fitness. The biomedical literature also frequently uses the 91 terms sex and gender interchangeably, with males and females more often than not referred to as men and women, or boys and girls (Khramtsova et al., 2019). There is therefore ample 92 93 scope for discipline-specific terms to be used for describing the same concept, which may hinder communication between disciplines and obscure examples of SA loci. Moreover, 94 95 although there has been some progress in introducing concepts from evolutionary biology into the field of medicine (Nesse and Williams, 1994), those inroads have been relatively 96 97 recent. It is therefore likely that the concepts of (intralocus) sexual conflict and sexual 98 antagonism are not generally well known within biomedical science, and variants that may 99 have SA effects on disease risk may not be referred to as such. A secondary related hypothesis

100 is that SA effects, when discovered, are discounted as errors as they do not match expectations that sex-differences in phenotype or genetic architecture are not important 101 102 (Clayton and Collins, 2014). As a result, that may also lead them to be misclassified or simply 103 go unreported, leading to a general publication bias.

104 For these reasons, we propose that a systematic review of the biomedical literature 105 to identify SA loci in humans requires a specific and targeted set of search terms that would 106 not normally be used within the field of evolutionary biology. We test this assumption by 107 dividing our systematic review into two stages. In the first stage, we search for papers 108 identifying specific genetic loci using terms directly relating to the concept of sexual 109 antagonism and others utilized in evolutionary biology. We supplement this search with a 110 second stage, where we develop a set of terms that we hypothesize may capture the same 111 concept as sexual antagonism within the biomedical literature, although not explicitly stated 112 as such, as well as additional terminology relating to possible alternatives for describing the 113 two sexes. From our searches we also extracted data on sex-specific effect sizes and allele 114 frequencies. We were then able to explore how effect sizes varied for the same alleles 115 between the sexes, and test the prediction that SA alleles experiencing net positive selection 116 between the sexes may achieve higher equilibrium frequencies than alleles that experience 117 more symmetric or net negative patterns of selection (Morrow and Connallon, 2013). Our 118 systematic review aims to advance our understanding of SA genes in humans, which show considerable and largely unexplained diversity in sexual dimorphism for disease phenotypes 119 120 (Ober et al., 2006; Rigby and Kulathinal, 2015), but we also highlight how and why 121 interdisciplinary research (in this case between biology and medicine) can sometimes fail, 122 impeding scientific advances over significant periods of time.

Methods 123

124 For this systematic review we followed PRISMA guidance where possible (Moher et al., 2009). 125 PubMed (https://pubmed.ncbi.nlm.nih.gov/) was searched for articles on 2nd December 2020 126 with no time limit. The searches were carried out in two Stages, with the organism filter set to human in both stages. In Stage 1, eligible studies were required to report specific genetic 127 128 variants or haplotypes that were referred to as sexually antagonistic or were an example of 129 intralocus sexual conflict. To achieve this, we conducted a Boolean search for articles that 130 used the terms "sexual antagonism" OR "sexually antagonistic" OR "intralocus sexual conflict"

AND "locus" OR "loci", "gene" OR "snp" OR "polymorphism" OR "variant" OR "allele" in their 131 abstract or title. The Stage 1 search returned 34 articles in total (full search term in the 132 133 supplementary material; search is accessible output

134 https://pubmed.ncbi.nlm.nih.gov/collections/60255050/?sort=pubdate).

In Stage 2, studies were required to report specific genetic variants or haplotypes in 135 humans with opposite effects in the two sexes on either complex traits, the outcome of a 136 medical intervention, or disease risk/severity. We define complex traits as likely with a 137 polygenic genetic architecture but are not directly related to a disease phenotype. In this 138 139 second stage search terms were specifically designed to include papers from the biomedical 140 literature that may have been missed in the first stage because they do not report their 141 findings with terms normally found within the evolutionary biology literature. Again, we 142 conducted a Boolean search for articles that used terms in their title or abstract to describe an opposite or different effect in the two sexes ("sex dependent", "sex different", "gender-143 144 dependent", "sex AND opposite", or "gender AND opposite"), or that capture this concept 145 with alternative words for sex (("male AND female AND opposite" OR "men AND women AND 146 opposite" OR "boys AND girls AND opposite") AND ("locus" OR "loci" OR "gene" OR "snp" OR 147 "polymorphism" OR "variant" OR "allele")). Full details of the search terms used and the numbers of articles returned are provided in the supplementary material. The Stage 2 search 148 149 returned 881 papers (Figure 1) (full search term in the supplementary material; search output 150 is accessible at https://pubmed.ncbi.nlm.nih.gov/collections/60254985/?sort=pubdate).

151 The abstracts of the papers from Stage 1 were then examined by EM and from Stage 2 by JH, and any papers that had the possibility of reporting an opposite effect of a specific 152 genetic locus on a complex trait, medical intervention or on disease risk/severity were 153 154 considered for further screening. From Stage 1, no articles passed the screening. From Stage 2, shortlist 70 155 this screening produced а of candidate papers 156 (https://pubmed.ncbi.nlm.nih.gov/collections/57906298/?sort=pubdate) Both JH and EM 157 then reviewed all the full texts of these candidate papers in detail. Papers were included in the final list if they described a sex-opposite or SA effect linked to a specific genetic locus or 158 159 loci, and reported the effect to be statistically significant (at a P-value cut-off of <0.05). One 160 additional paper was considered from an outside source.

161

at

medRxiv preprint doi: https://doi.org/10.1101/2020.12.16.20248300; this version posted February 12, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in



Figure 1. PRISMA flow diagram for systematic review of sexually antagonistic loci in humans.

165 We converted all reported sex-specific effects into a standard effect size (Cohen's d) quantifying the magnitude of how a given variant affects the studied trait expressed in the 166 167 given sex. Specifically, Cohen's d was computed based on the reported descriptive statistics 168 (N, mean, standard error) or by conversion from other effect sizes (Odds ratio) and test 169 statistics (*F*-values, *t*-values) using formulas reported elsewhere (Borenstein, 2009; Gurevitch 170 et al., 2013, pp. 195–206; Lajeunesse, 2013). We sought information directly from the authors 171 where these metrics were not possible to extract from the papers themselves (12 authors contacted, 5 responded, 3 responded with data, all later excluded as they did not fulfil the 172 173 criteria for eligibility). We also recorded the gene name, locus (with accession/rs number 174 where possible), trait affected and the frequency of the focal allele having the effect, 175 hereafter referred to as *effect allele frequency*. Identification for the variants were taken from 176 the studies where possible, but others necessitated searching the National Centre for 177 Biotechnology Information (NCBI) to find the Reference SNP cluster ID for the variants 178 described. Where effect allele frequencies were not reported, we used genotype frequencies 179 to calculate effect allele frequency. Not all studies reported allele or genotype frequencies 180 and so we attempted to supplement these data with allele frequencies from the 1000 181 genomes database (Auton et al., 2015), since these show a strong correlation with effect allele 182 frequencies reported in the studies reviewed (Pearson correlation: N = 25 r = 0.94, P > 0.001; 183 Figure S1). However, using this approach we were only able to supplement our allele frequency data for one additional locus (rs7341475 in the RELN gene; Table 1). 184

185 If $b_{\rm f}$ and $b_{\rm m}$ represent the estimated effect of the focal allele in females and males respectively, then positive values of $b_{\rm f}$ or $b_{\rm m}$ imply that the allele is positively associated with 186 187 disease expression, whereas negative values imply that the allele is negatively associated with 188 disease expression. SA alleles are therefore defined as those with opposite effects between the sexes (i.e. $b_f < 0 < b_m$ or $b_m < 0 < b_f$). An evolutionary model of evolution at SA loci predicts 189 190 that as the magnitude of the positive effect that an SA allele has outweighs the negative effect, the higher the frequency that allele can achieve (Morrow and Connallon, 2013). We 191 192 therefore expect a negative relationship between the ratio of positive to negative effect sizes (hereafter referred to as the *effect size ratio*) and observed allele frequency. To investigate 193 194 this, we calculated the effect size ratio by dividing the positive standardized effect size by the 195 negative standardized effect size; when $b_f < 0 < b_m$ effect size ratio was calculated as b_m / b_f , 196 and when $b_m < 0 < b_f$ effect size ratio was calculated as b_f / b_m .

197 **Table 1. Genetic loci in humans showing sexually antagonistic effects on trait expression.** EAF, effect allele frequency (* indicates allele

198 frequency derived from 100 genomes database); M, male; F, female. Background colours denote instances where genes and/or variants 199 appear more than once in the list.

Trait	Gene	Locus	EAF	M Effect	M Effect SE	F Effect	F Effect SE	Reference
Complex traits								
Concentration performance score	FADS1/2	rs1535	0.672	0.2275	0.1065	-0.2394	0.1116	(Lauritzen et al., 2017)
Reading speed, number of sentences	FADS1/2	rs174448	0.642	0.5511	0.1069	-0.6074	0.1129	(Lauritzen et al., 2017)
Reading speed, number of sentences	ELOVL5	rs2397142	0.695	-0.1963	0.1042	0.2364	0.1095	(Lauritzen et al., 2017)
Reading speed, correct sentences	FADS1/2	rs174448	0.642	0.6599	0.1077	-0.3451	0.1112	(Lauritzen et al., 2017)
Speed-dating success	OPRM1	rs1799971	0.922	0.4697	0.2275	-0.53	0.2856	(Wu et al., 2016)
Speed-dating success	HTR2A	rs6311	0.418	-0.4826	0.1982	0.4702	0.1964	(Wu et al., 2016)
Waist-hip-ratio (BMI adjusted)	SIM1	rs17185536	0.76	-0.0166	0.008	0.0264	0.0067	(Winkler et al., 2015)
Waist-hip-ratio (BMI adjusted)	NMU	rs3805389	0.28	-0.0139	0.0067	0.0261	0.006	(Winkler et al., 2015)
Waist-hip-ratio (BMI adjusted)	GNPNAT1	rs4898764	0.53	0.0208	0.0066	-0.0165	0.0059	(Winkler et al., 2015)
Waist-hip-ratio (BMI adjusted)	SGCZ	rs17470444	0.71	0.0345	0.0081	-0.0149	0.0068	(Winkler et al., 2015)
Waist-hip-ratio (BMI adjusted)	IQGAP2	rs2069664	0.53	0.0244	0.0078	-0.0183	0.0067	(Winkler et al., 2015)
Waist-hip-ratio (BMI adjusted)	SLC2A3	rs741361	0.6	0.0272	0.0079	-0.0196	0.0067	(Winkler et al., 2015)
Waist-hip-ratio (BMI adjusted)	IRS1	rs2673140	0.38	0.022	0.0066	-0.0209	0.0059	(Winkler et al., 2015)
Waist-hip-ratio (BMI adjusted)	TTN	rs2042995	0.23	0.0198	0.0066	-0.022	0.0078	(Winkler et al., 2015)
Waist-hip-ratio (BMI adjusted)	RXRA	rs10881574	0.07	0.0268	0.008	-0.0191	0.0067	(Winkler et al., 2015)
Waist-hip-ratio (BMI adjusted)	PTPRD	rs7042428	0.98	0.0244	0.0071	-0.0166	0.0063	(Winkler et al., 2015)
Waist-hip-ratio (BMI adjusted)	CECR2	rs17809093	0.04	0.0294	0.0091	-0.024	0.0077	(Winkler et al., 2015)
Reaction time (RT) in the Stroop task, congruent condition	CHRNA5	rs3841324	0.406	-1.5421	0.3857	0.9945	0.2517	(Schneider et al., 2015)
Reaction time (RT) in the Stroop task, incongruent condition	CHRNA5	rs3841324	0.406	-1.6215	0.389	1.0215	0.2521	(Schneider et al., 2015)
Reaction time (RT) in the Negative priming task	CHRNA5	rs3841324	0.406	-1.675	0.3912	0.6299	0.247	(Schneider et al., 2015)

Borderline personality traits after maltreatment	OXTR	rs53576	0.738	-0.3429	0.0881	0.2066	0.0857	(Cicchetti et al., 2014)
Borderline personality traits after maltreatment	FKBP5	CATT haplotype	-	0.2041	0.0877	-0.195	0.0857	(Cicchetti et al., 2014)
fluid intelligence	C16orf62 (OXTR)	rs226849	0.46	-0.3949	0.1869	0.494	0.1814	(Kiy et al., 2013)
face perception	C16orf62 (OXTR)	rs226849	0.46	-0.5819	0.1909	0.3498	0.1788	(Kiy et al., 2013)
face memory	C16orf62 (OXTR)	rs226849	0.46	-0.3679	0.1864	0.3562	0.1789	(Kiy et al., 2013)
Hippocampal volume	SLC6A4	rs25531	0.39	-		-		(Price et al., 2013)
Sociopathy (in alcoholics)	SLC6A4	rs25531	0.51	-		-		(Herman et al., 2011)
systolic blood pressure S_NIGHT	PON1	rs3917542	-	-0.1047	0.0637	0.1129	0.0645	(Padmanabhan et al., 2010)
systolic blood pressure S_NIGHT	PON3	rs17884563	-	-0.1482	0.0637	0.1061	0.0645	(Padmanabhan et al., 2010)
systolic blood pressure S_CLIN	EDNRB	rs1335803	-	-0.1308	0.0637	0.1129	0.0645	(Padmanabhan et al., 2010)
diastolic blood pressure D_NIGHT	DRD1	rs265974	-	-0.1482	0.0637	0.1502	0.0646	(Padmanabhan et al., 2010)
diastolic blood pressure D_HOME	SLC4A2	rs2303933	-	-0.1482	0.0637	0.1325	0.0646	(Padmanabhan et al., 2010)
diastolic blood pressure D_CLIN	LPL	rs17410577	-	-0.1047	0.0637	0.1775	0.0647	(Padmanabhan et al., 2010)
Psychological Stress	BDNF	rs6265	0.149	-		-		(Shalev et al., 2009)
BMI standard deviation score (children)	FAS	rs2228305	0.0312	-0.552	0.2259	0.4427	0.2075	(Korner et al., 2007)
Pain sensitivity	OPRM1	rs1799971	0.8817	-		-		(Fillingim et al., 2005)
Central DBP	REN	rs6693954	0.22	-0.4444	0.2132	1.1052	0.3923	(Ljungberg et al., 2014)
Disease risk/severity								
Graves opthalmopathy in GD	PRR3	rs2074503	0.3586	0.4397	0.1682	-0.2185	0.0851	(Liu et al., 2014)
Colorectal cancer	LTA	rs1041981	0.32	-0.0722	0.0368	0.1027	0.0453	(Sainz et al., 2012)
Arterial blood pressure	PPAR	rs1801282	0.1213	-		-		(Franck et al., 2012)
Schizophrenia risk	RELN	rs7341475	0.851*	1.2396	0.2819	-0.762	0.3662	(Ovadia and Shifman, 2011)
Colon cancer survival	ESR2	(CA)n repeats	-	0.2272	0.0962	-0.2046	0.1205	(Press et al., 2011)
Schizophrenia risk	DAO	rs2070586	0.2729	0.1982	0.0888	-0.2537	0.0908	(Kim et al., 2010)

T2DM, fasting glucose	SCARB1	rs9919713	0.04	0.1865	0.0853	-0.2515	0.0697	(McCarthy et al., 2009)
Depression	SLC6A4	rs25531	0.4586	0.5404	0.2277	-0.3996	0.1859	(Sjoberg et al., 2006)
Infertility in cystic fibrosis	CFTR	rs213950	0.417931	-		-		(Morea et al., 2005)
Bone mineral density	APOE	rs429358	0.0798	-		-		(Wong et al., 2005)
Narcolepsy severity	COMT	Long allele	0.4588	1.3596	0.3878	-2.2152	0.4871	(Dauvilliers et al., 2001)
Nonsyndromic cleft lip	ІМРК	rs11142081	0.863	1.2156	0.0937	-1.1161	0.0783	(Carlson et al., 2018)
Nonsyndromic cleft lip	ІМРК	rs72804706	0.898	-0.816	0.0906	2.0665	0.0908	(Carlson et al., 2018)
Nonsyndromic cleft lip	ІМРК	rs77590619	0.744	-0.8577	0.0904	1.2291	0.0804	(Carlson et al., 2018)
Allergy	ACP1	A* allele (CG haplotype)	-	-		-		(Gloria-Bottini et al., 2007)
Hepatitis C susceptability	IL-12B	rs3212227	0.3463	-		-		(Youssef et al., 2013)
RSV severity	IL-9	rs2069885	0.15	0.1888	0.0933	-0.2794	0.0957	(Schuurhof et al., 2010)
CV risk marker (plasma fatty acid composition)	FABP2	rs1799883	0.287	-		-		(Gastaldi et al., 2007)
Bone mineral density	NR3C1	GCAG haplotype	-	0.6854	0.3676	-0.9029	0.4311	(Peng et al., 2008)
Anxiety	NGF	rs6330	0.451	0.4562	0.18	-0.4674	0.1817	(Lang et al., 2008)
Melanoma risk	RNASEL, miR-146a	AG/AA and C haplotype	-	0.4525	0.1564	-0.3553	0.174	(Sangalli et al., 2017)

Thus, SA alleles with a greater beneficial effect will have a smaller, more negative effect size ratio (<-1), while SA alleles that have a greater deleterious effect will have a larger effect size ratio (>-1), up to a maximum value of 0 (positive values occur when the effect is positive or negative in both sexes, but the allele would then no longer be defined as a SA allele).

207 We modelled how effect allele frequency changes with effect size ratio using a 208 generalized linear model (GLM), weighted by the inverse of the variance of the effect sizes 209 such that data points with smaller variance have a higher weight, since smaller sample sizes were associated with larger and more variable effect sizes (Figure S2). We initially also 210 211 included trait class and its interaction with effect size ratio as a fixed factor with two levels 212 (complex trait and disease trait/severity), since alleles that influence complex traits in 213 opposite directions are not necessarily under SA selection and so may not behave in the way 214 predicted, whereas alleles influencing disease traits, unless very late acting, are more likely 215 to show a closer relationship with marginal effects on fitness. As a response variable, effect 216 allele frequency is limited between 0 and 1, so we looked at allele counts to allow allele 217 frequency to vary freely. GLMs with binomial error distribution showed substantial 218 overdispersion, so we used a quasibinomial function to address this issue (Payne et al., 2018). 219 We used a Chi-squared test to infer significance of the two predictor variables and their 220 interaction. The full model indicated that the interaction term and trait class have no 221 significant effect, so that we report the fit of the reduced model which only includes effect 222 size ratio. We also subsequently modelled the data for the two trait classes (complex traits 223 and disease risk/severity) separately, again using a quasibinomial distribution function, to see 224 if the result was replicated in these smaller subsets of the data. The raw data and R script is 225 available for replicating the analyses and figures we present (Supplementary Material).

226 Results

227 The Stage 1 search found no articles that described genetic loci in humans with effects that 228 were sexually antagonistic. In contrast, the Stage 2 search identified 32 articles that described 229 variants with statistically significant sex-opposite or SA effects (Figure 1; 230 https://pubmed.ncbi.nlm.nih.gov/collections/60278165/?sort=pubdate). From the studies 231 examined, 51 SA variants were identified (Table 1), affecting 21 different complex traits (30 232 loci) and 19 disease risk/severity traits (21 loci), with a large range of effect sizes. There were

233 no variants affecting medical intervention traits that passed the screening process. The 234 majority of alleles had effect sizes of similar absolute values in the two sexes, with larger 235 effects tending to show greater differences on absolute effect size (Figure S3).

236 We found 22 studies provided sufficient data to allow the relationship between effect size ratio and effect allele frequency to be explored by statistical modelling. Trait class and its 237 interaction with effect size ratio were initially included in the model but neither were found 238 to have a significant effect (GLM: trait class dfs = 1,35, deviance = 15.5×10^3 , P = 0.965; 239 240 interaction dfs = 1,34, deviance = 1476, P = 0.989) and were therefore excluded from the subsequent model in which effect size ratio was found to relate negatively to effect allele 241 242 frequency, as predicted (GLM: estimate \pm SE = -1.10 \pm 0.50, dfs = 1,36, deviance = 38.7 \times 10⁶, 243 P = 0.024; Figure 2). For three loci there were data on effect sizes for more than one trait 244 (Table 1), which introduced a degree of non-independence between these values in the 245 dataset. However, resampling the data with effect sizes for only one trait for these three loci 246 in turn and modelling these datasets in the same way (18 individual GLMs, dfs = 1,31) did not 247 change the results qualitatively (minimum, maximum: model estimate = -1.0963, -1.0964; 248 deviance = 38.72×10^6 , 38.73×10^6 ; *P* = 0.03618, 0.03620).

249 Although the interaction term between trait type and effect size ratio was not significant we wanted to investigate whether the negative relationship between effect size 250 251 ratio and effect allele frequency across all loci was repeated when the data was divided 252 according to trait class, since while opposite effects on disease risk/severity may show a direct relationship with SA fitness effects, complex traits may or may not be experiencing SA 253 254 selection, even if effects are in opposite directions in the two sexes. However, although the 255 trends were both again negative as predicted, the generalized linear models of these smaller 256 datasets were only marginally significant (complex traits model estimate \pm SE = -1.10 \pm 0.61, dfs = 1,24, deviance = 38.7×106 , P = 0.065; disease risk/severity model estimate \pm SE = -1.34 257 258 \pm 0.77, dfs = 1,10, deviance = 5.14 \times 104, P = 0.053; Figure S4). As for the full dataset, there was some lack of independence for the complex traits subset which contained loci with effect 259 sizes for more than one trait. Again, resampling and modelling these datasets in the same 260 way (18 individual glms, dfs 1, 22) did not change the results quantitatively (minimum, 261 maximum: model estimate = -1.0960, -1.0961; deviance = 38.669 × 10⁶, 38.675 × 10⁶; P = 262 263 0.07774, 0.07776).





265 Figure 2. The relationship between effect allele frequency and effect size ratio. Point size varies according to the variance of effect size ratio - larger points have smaller variance and 266 therefore a larger weighting in the model. The vertical dotted line represents the switch point 267 268 between a net-negative effect of a particular locus (effect size ratio >-1) and a net positive 269 effect (effect size ratio <-1). The blue line represents the predicted values derived from the 270 generalized linear model fitted to the data (see Results).

Discussion 271

272 The Stage 1 literature search of our systematic review focussed on finding reports of specific 273 genetic loci in humans with evidence for SA effects using terminology normally associated 274 with the evolutionary concepts of sexual conflict or sexual antagonism. The Stage 2 search 275 sought equivalent evidence, but used search terms that we anticipated would be used by 276 scientists outside the field of evolutionary biology, who may not use the same terminology. 277 Although the Stage 1 search did not find any examples of SA loci occurring in humans, the 278 Stage 2 search identified 51 genetic loci across 39 studies that had ostensibly SA effects, but 279 were not described as such. Clearly then the Stage 1 review failed to identify multiple relevant 280 reports going back some 20 years because the terminology used in those reports did not 281 match the conceptual framework of the search. The Stage 2 search may also be a lower limit 282 given searches of other larger databases may also harbour further examples (see below). 283 Although not yet validated, these reports nonetheless represent a substantial body of 284 evidence that humans, like other organisms with separate sexes (Bonduriansky and 285 Chenoweth, 2009), inevitably experience SA selection for a wide range of complex traits 286 (Connallon and Clark, 2014; Garver-Apgar et al., 2011; Stearns et al., 2012; Stulp et al., 2012), 287 as well as for a range of diseases.

288 A key prediction from a population genetic model of SA genetic variation is that SA 289 alleles are expected to achieve higher equilibrium frequencies, without necessarily going to 290 fixation, as the relative magnitude of the positive effect in one sex outweighs the negative effect in the opposite sex i.e. an increasingly negative effect size ratio (Morrow and Connallon, 291 292 2013). We found clear support for this prediction, with a negative relationship between effect 293 size ratio and allele frequency when examining all complex traits and diseases together (Fig 294 2), although this relationship was only marginally significant when complex or disease trait 295 classes were modelled separately (Fig S3). These results lend support to the view that the loci 296 identified are genuinely experiencing SA selection, and although it is difficult to discern how 297 selection acts on trait size in males and females for complex traits we would not expect the 298 frequencies of disease-causing alleles to be so high under a mutation-selection balance. We 299 were not able to look at the evolutionary history or age of these alleles due to limited 300 information (n = 8) (Albers and McVean, 2018), it would nonetheless be valuable to examine 301 the population dynamics of these alleles over a broad timescale.

302 The loci showed a very broad range of effect sizes, from small to very large, with a generally symmetrical inverse relationship between effect size in one sex and the other 303 304 (Figure S2), which is generally expected, since our screening process necessarily excluded 305 studies reporting effects in the same direction across the two sexes. Nonetheless, it is striking just how large some of the effects were, with very large negative effects in one sex 306 307 simultaneously occurring with similarly large positive effects. Larger and more variable effect 308 sizes are expected when sample sizes are small, a pattern we also found, which motivates 309 further investigation of the traits and loci included in this review to elucidate more accurate estimates of real effect sizes. 310

311 The loci themselves fall within genes that influence a broad range of phenotypes, 312 including morphological, physiological and behavioural complex traits, and a similarly diverse 313 range of disease types, including various cancers, neurological disorders and immune system 314 processes (see Table 1). For the most part, the diseases appear to be early-acting rather than 315 late-onset, with the exception of perhaps bone mineral density. As such, it seems reasonable 316 that an allele that increases disease risk or severity in these cases will indeed have a 317 concomitant reduction in marginal fitness. Although a single large study identified several loci 318 related to BMI adjusted waist-to-hip ratio, there is generally no overall bias towards one 319 particular trait or disease class. The total number of loci is relatively small however, which 320 may limit power to identify such biases if they exist. We also did not find any examples of SA 321 loci on the X-chromosome, which may or may not be a hotspot of sexual antagonism (Fry, 322 2010; Rice, 1984; Ruzicka and Connallon, 2020). This was expected given that it is commonly not included in genome-wide analyses (Wise et al., 2013), although most of the papers we 323 reviewed were candidate gene studies. Nonetheless, we anticipate further examples may be 324 325 identified should data from the X-chromosome be included systematically in association studies. 326

We also found evidence that some traits are influenced by more than one genetic variant in sex-opposite or SA ways (n=8), or that some specific variants have pleiotropic effects on more than one trait or disease in a sex-opposite or SA way (n=6; see Table 1). This complexity in the genetic architecture of traits or diseases may make conflict resolution particularly difficult, as a change in the allele at a single genetic locus experiencing SA selection may simultaneously influence multiple genes or phenotypes in both sexes in divergent ways (Fitzpatrick, 2004; Pennell and Morrow, 2013). Consequently, this may explain

334 the persistence of intralocus sexual conflict at these loci. It may be that some of the remaining 335 loci also have as yet unidentified pleiotropic effects with other traits or there are as yet 336 unidentified SA loci influencing those same traits or diseases. Of the 51 variants identified, 4 337 were confirmed to be haplotypes. Such variants, consisting of two or more SNPs in linkage 338 disequilibrium having a joint effect, could also present a problem for conflict resolution, since 339 the ability of selection to act on any individual locus independent of the others in the linkage 340 block is reduced for linked loci. This issue may also extend to other single variants reported here if they also occur in linkage blocks. 341

342 Although we have identified multiple genetic loci with either sex-opposite or SA 343 effects these are likely outnumbered by those with either sex-specific (same direction but 344 different magnitude) or sex-limited effects. For instance, Winkler et al. (2015) report 44 loci 345 with sex-specific or sex-limited effects but only 11 with sex-opposite effects. Several other 346 genome-wide association studies report sex-specific effects in several human diseases 347 (Khramtsova et al., 2019), and a recent (non-systematic) review identified 37 SNPs with sex-348 dependent effects (Gilks et al., 2014). Detection of loci with SA versus sex-specific or sex-349 limited effects may differ systematically since we expect SA loci are more likely to persist at 350 intermediate frequencies than loci with sex-specific effects (i.e. that differ between the sexes 351 in magnitude but not sign). A larger systematic review that targeted variants with sex-specific 352 or sex-dependent effects would therefore be a valuable contribution and enable us to more 353 clearly understand how important SA alleles are relative to the broader context of genes with 354 non-identical effects in the two sexes.

A key gap in our knowledge is whether the putative examples of sex-opposite or SA 355 alleles presented here can be validated using independently derived datasets in the same or 356 357 different sub-populations. For this, focussing on those variants associated with sex-358 differential disease risk would naturally be the most fruitful for advancing our knowledge of sexual antagonism in human disease. We therefore encourage specialists for the particular 359 360 disease groups presented in Table 1 to include in the future the potential for SA genetic effects to occur when designing studies and analysing data. It is also important for all studies 361 to report results in sufficient detail so that effect sizes can be calculated (if not given) as well 362 as allele frequency data. Unfortunately, 17 studies failed to do this, so could not be included 363 364 in our review and subsequent test of the evolutionary model. More generally, our study 365 reinforces the view that sex is an important factor in shaping genetic associations with human

traits and disease, even in divergent and contradictory ways, and so should always be
considered when investigators examine genetic associations with phenotypes (Lee, 2018;
Ober et al., 2008).

369 There is a possibility that some bias exists in the PubMed database against papers from the field of evolutionary biology, and if we had used another database then both stages 370 would have returned valid papers. We subsequently (14th Dec 2020) sought to investigate this 371 372 possibility with additional searches of Scopus and Web of Science. Repeating the Stage 1 search initially returned 85 papers in Web of Science (Basic search of Topic, refined by 373 374 "Human" within results) and 71 papers in Scopus (include keywords "Human", exclude "Non-375 Human"), but again no papers made it through the screening process. Repeating the Stage 2 376 search returned a much larger number of studies in both Web of Science (4,573; Basic search 377 of Topic, refined by "Human" within results) and Scopus (6,616; Advanced search of Title-378 Abstract, filter: include human and humans, exclude nonhumans, Articles only), with 8,604 379 unique records. This large number of records is too many to currently screen and may harbour 380 further examples of SA loci in humans, but it is noteworthy that the majority of the initial list 381 of studies found during Stage 2 using PubMed were also found in the other two databases 382 (712 out of 881) as well as 28 out of the screened list of 32 studies identified in the current 383 systematic review.

384 The disparity between the two stages of the review process provides a remarkable example of how discipline-specific terminology and concepts can hinder scientific 385 386 communication between fields for substantial periods of time. For many of the studies identified in this review, the focus of the research was not on quantifying or even identifying 387 sex-specific genetic effects in traits or disease, although they were tested for. The responses 388 389 to such findings varied. Some framed these results as a major finding, others merely made 390 note of them, with one suggesting that since the genetic associations were in opposite 391 directions in the two sexes then it should be regarded as a false positive (Wong et al., 2005). 392 It is possible, or even likely then that there exists a publication bias in the biomedical sciences 393 against studies with apparently incongruous sex-opposite or SA effects, perhaps in part 394 because the evolutionary framework that may provide a context for understanding those results is not generally appreciated or known. Of course, for evolutionary biologists interested 395 396 in the role of SA selection on human traits and disease, this is clearly a problem. For many 397 years no specific examples of SA loci were known in humans, and yet the first putative

examples in fact appeared in the literature two decades ago. Our systematic review therefore
provides a concrete illustration of how advances to both fields have likely been hampered by
a limited understanding of the theoretical framework and terminology used by the
neighbouring field.

402 How can communication between the fields of medicine and evolutionary biology be facilitated? We do not have a comprehensive answer but clearly training in, or an increased 403 awareness of, evolutionary medicine for scientists in both camps would probably be 404 405 beneficial. The topic of evolutionary biology now forms a key part of the education for some 406 biomedical scientists and clinicians. Similarly, evolutionary medicine is now frequently 407 included in fundamental textbooks on evolution, and is being taught to students of 408 evolutionary biology as part of their degree courses. These changes have been relatively 409 recent, are far from being universally employed, but they should be encouraged. Funders of primary research are also now actively encouraging or obliging researchers to include sex as 410 411 a factor when designing their studies (Clayton and Collins, 2014), although this may simply 412 result in studies that aim to control for rather than investigate these effects explicitly. 413 Consequently even this remedy may still preclude a deeper understanding of the origins of 414 some human diseases.

415

416 Acknowledgements

We thank Jessica Abbott, Tim Connallon and Filip Ruzicka for comments on a previous version
of the MS. Funding was provided by the Swedish Research Council (Grant number: 201903567) and by the Royal Society to EHM as a University Research Fellowship and
Enhancement Award. TJ was funded by the Centre national de la recherche scientifique
(CNRS) and the German Research Foundation (DFG grant number: JA 2653/2-1).

422

423 Competing Interest Statement

424 The authors have declared no competing interest.

References 426

427 Albers, P.K., McVean, G., 2018. Dating genomic variants and shared ancestry in population-428 scale sequencing data (preprint). Genomics. https://doi.org/10.1101/416610 429 Auton, A., Abecasis, G.R., Altshuler, D.M., Durbin, R.M., Abecasis, G.R., Bentley, D.R., 430 Chakravarti, A., Clark, A.G., Donnelly, P., Eichler, E.E., Flicek, P., Gabriel, S.B., Gibbs, 431 R.A., Green, E.D., Hurles, M.E., Knoppers, B.M., Korbel, J.O., Lander, E.S., Lee, C., 432 Lehrach, H., Mardis, E.R., Marth, G.T., McVean, G.A., Nickerson, D.A., Schmidt, J.P., 433 Sherry, S.T., Wang, J., Wilson, R.K., Gibbs, R.A., Boerwinkle, E., Doddapaneni, H., Han, 434 Y., Korchina, V., Kovar, C., Lee, S., Muzny, D., Reid, J.G., Zhu, Y., Wang, J., Chang, Y., 435 Feng, Q., Fang, X., Guo, X., Jian, M., Jiang, H., Jin, X., Lan, T., Li, G., Li, J., Li, Y., Liu, S., 436 Liu, X., Lu, Y., Ma, X., Tang, M., Wang, B., Wang, G., Wu, H., Wu, R., Xu, X., Yin, Y., 437 Zhang, D., Zhang, W., Zhao, J., Zhao, M., Zheng, X., Lander, E.S., Altshuler, D.M., 438 Gabriel, S.B., Gupta, N., Gharani, N., Toji, L.H., Gerry, N.P., Resch, A.M., Flicek, P., 439 Barker, J., Clarke, L., Gil, L., Hunt, S.E., Kelman, G., Kulesha, E., Leinonen, R., McLaren, 440 W.M., Radhakrishnan, R., Roa, A., Smirnov, D., Smith, R.E., Streeter, I., Thormann, A., 441 Toneva, I., Vaughan, B., Zheng-Bradley, X., Bentley, D.R., Grocock, R., Humphray, S., 442 James, T., Kingsbury, Z., Lehrach, H., Sudbrak, R., Albrecht, M.W., Amstislavskiy, V.S., 443 Borodina, T.A., Lienhard, M., Mertes, F., Sultan, M., Timmermann, B., Yaspo, M.-L., 444 Mardis, E.R., Wilson, R.K., Fulton, L., Fulton, R., Sherry, S.T., Ananiev, V., Belaia, Z., 445 Beloslyudtsev, D., Bouk, N., Chen, C., Church, D., Cohen, R., Cook, C., Garner, J., 446 Hefferon, T., Kimelman, M., Liu, C., Lopez, J., Meric, P., O'Sullivan, C., Ostapchuk, Y., 447 Phan, L., Ponomarov, S., Schneider, V., Shekhtman, E., Sirotkin, K., Slotta, D., Zhang, 448 H., McVean, G.A., Durbin, R.M., Balasubramaniam, S., Burton, J., Danecek, P., Keane, 449 T.M., Kolb-Kokocinski, A., McCarthy, S., Stalker, J., Quail, M., Schmidt, J.P., Davies, 450 C.J., Gollub, J., Webster, T., Wong, B., Zhan, Y., Auton, A., Campbell, C.L., Kong, Y., 451 Marcketta, A., Gibbs, R.A., Yu, F., Antunes, L., Bainbridge, M., Muzny, D., Sabo, A., 452 Huang, Z., Wang, J., Coin, L.J.M., Fang, L., Guo, X., Jin, X., Li, G., Li, Q., Li, Y., Li, Z., Lin, 453 H., Liu, B., Luo, R., Shao, H., Xie, Y., Ye, C., Yu, C., Zhang, F., Zheng, H., Zhu, H., Alkan, C., Dal, E., Kahveci, F., Marth, G.T., Garrison, E.P., Kural, D., Lee, W.-P., Fung Leong, 454 455 W., Stromberg, M., Ward, A.N., Wu, J., Zhang, M., Daly, M.J., DePristo, M.A., 456 Handsaker, R.E., Altshuler, D.M., Banks, E., Bhatia, G., del Angel, G., Gabriel, S.B., 457 Genovese, G., Gupta, N., Li, H., Kashin, S., Lander, E.S., McCarroll, S.A., Nemesh, J.C., 458 Poplin, R.E., Yoon, S.C., Lihm, J., Makarov, V., Clark, A.G., Gottipati, S., Keinan, A., 459 Rodriguez-Flores, J.L., Korbel, J.O., Rausch, T., Fritz, M.H., Stütz, A.M., Flicek, P., Beal, 460 K., Clarke, L., Datta, A., Herrero, J., McLaren, W.M., Ritchie, G.R.S., Smith, R.E., 461 Zerbino, D., Zheng-Bradley, X., Sabeti, P.C., Shlyakhter, I., Schaffner, S.F., Vitti, J., 462 Cooper, D.N., Ball, E.V., Stenson, P.D., Bentley, D.R., Barnes, B., Bauer, M., Keira 463 Cheetham, R., Cox, A., Eberle, M., Humphray, S., Kahn, S., Murray, L., Peden, J., 464 Shaw, R., Kenny, E.E., Batzer, M.A., Konkel, M.K., Walker, J.A., MacArthur, D.G., Lek, 465 M., Sudbrak, R., Amstislavskiy, V.S., Herwig, R., Mardis, E.R., Ding, L., Koboldt, D.C., 466 Larson, D., Ye, K., Gravel, S., The 1000 Genomes Project Consortium, Corresponding 467 authors, Steering committee, Production group, Baylor College of Medicine, BGI-468 Shenzhen, Broad Institute of MIT and Harvard, Coriell Institute for Medical Research, 469 European Molecular Biology Laboratory, E.B.I., Illumina, Max Planck Institute for 470 Molecular Genetics, McDonnell Genome Institute at Washington University, US 471 National Institutes of Health, University of Oxford, Wellcome Trust Sanger Institute,

472	Analysis group, Affymetrix, Albert Einstein College of Medicine, Bilkent University,
473	Boston College, Cold Spring Harbor Laboratory, Cornell University, European
474	Molecular Biology Laboratory, Harvard University, Human Gene Mutation Database,
475	Icahn School of Medicine at Mount Sinai, Louisiana State University, Massachusetts
476	General Hospital, McGill University, National Eye Institute, N., 2015. A global
477	reference for human genetic variation. Nature 526, 68–74.
478	https://doi.org/10.1038/nature15393
479	Barson, N.J., Aykanat, T., Hindar, K., Baranski, M., Bolstad, G.H., Fiske, P., Jacq, C., Jensen,
480	A.J., Johnston, S.E., Karlsson, S., Kent, M., Moen, T., Niemelä, E., Nome, T., Næsje,
481	T.F., Orell, P., Romakkaniemi, A., Sægrov, H., Urdal, K., Erkinaro, J., Lien, S., Primmer,
482	C.R., 2015. Sex-dependent dominance at a single locus maintains variation in age at
483	maturity in salmon. Nature 528, 405–408. https://doi.org/10.1038/nature16062
484	Bonduriansky, R., Chenoweth, S.F., 2009. Intralocus sexual conflict. Trends Ecol Evol 24,
485	280–288.
486	Borenstein, M., 2009. Converting Among Effect Sizes, in: Introduction to Meta-Analysis. John
487	Wiley & Sons, Ltd, pp. 45–49. https://doi.org/10.1002/9780470743386.ch7
488	Camus, M.F., Wolf, J.B.W., Morrow, E.H., Dowling, D.K., 2015. Single Nucleotides in the
489	mtDNA Sequence Modify Mitochondrial Molecular Function and Are Associated with
490	Sex-Specific Effects on Fertility and Aging. Curr. Biol. 25, 2717–2722.
490 491	https://doi.org/10.1016/j.cub.2015.09.012
491	
	Carlson, J.C., Nidey, N.L., Butali, A., Buxo, C.J., Christensen, K., Deleyiannis, F.WD., Hecht,
493	J.T., Field, L.L., Moreno-Uribe, L.M., Orioli, I.M., Poletta, F.A., Padilla, C., Vieira, A.R.,
494	Weinberg, S.M., Wehby, G.L., Feingold, E., Murray, J.C., Marazita, M.L., Leslie, E.J.,
495	2018. Genome-wide interaction studies identify sex-specific risk alleles for
496	nonsyndromic orofacial clefts. Genet. Epidemiol. 42, 664–672.
497	https://doi.org/10.1002/gepi.22158
498	Chippindale, A.K., Gibson, J.R., Rice, W.R., 2001. Negative genetic correlation for adult
499	fitness between sexes reveals ontogenetic conflict in Drosophila. Proc. Natl. Acad.
500	Sci. USA 98, 1671–1675.
501	Cicchetti, D., Rogosch, F.A., Hecht, K.F., Crick, N.R., Hetzel, S., 2014. Moderation of
502	maltreatment effects on childhood borderline personality symptoms by gender and
503	oxytocin receptor and FK506 binding protein 5 genes. Dev. Psychopathol. 26, 831–
504	849. https://doi.org/10.1017/S095457941400042X
505	Clayton, J.A., Collins, F.S., 2014. Policy: NIH to balance sex in cell and animal studies. Nature
506	509, 282–283. https://doi.org/10.1038/509282a
507	Connallon, T., Clark, A., G., 2014. Evolutionary inevitability of sexual antagonism. Proc. R.
508	Soc. B Biol. Sci. 281, 20132123. https://doi.org/10.1098/rspb.2013.2123
509	Connallon, T., Clark, A.G., 2013. Antagonistic Versus Nonantagonistic Models of Balancing
510	Selection: Characterizing the Relative Timescales and Hitchhiking Effects of Partial
511	Selective Sweeps. Evolution 67, 908–917. https://doi.org/10.1111/j.1558-
512	5646.2012.01800.x
513	Dauvilliers, Y., Neidhart, E., Lecendreux, M., Billiard, M., Tafti, M., 2001. MAO-A and COMT
514	polymorphisms and gene effects in narcolepsy. Mol. Psychiatry 6, 367–372.
515	https://doi.org/10.1038/sj.mp.4000911
516	Dixson, A., 2009. Dixson, A. F. (2009) Sexual selection and the Origins of Human Mating
517	Systems. Oxford University Press, UK.

518	Ellegren, H., Parsch, J., 2007. The evolution of sex-biased genes and sex-biased gene
519	expression. Nat Rev Genet 8, 689–698. https://doi.org/10.1038/nrg2167
520	Fillingim, R.B., Kaplan, L., Staud, R., Ness, T.J., Glover, T.L., Campbell, C.M., Mogil, J.S.,
521	Wallace, M.R., 2005. The A118G single nucleotide polymorphism of the mu-opioid
522	receptor gene (OPRM1) is associated with pressure pain sensitivity in humans. J. Pain
523	Off. J. Am. Pain Soc. 6, 159–167. https://doi.org/10.1016/j.jpain.2004.11.008
524	Fitzpatrick, M.J., 2004. Pleiotropy and the genomic location of sexually selected genes. Am.
525	Nat. 163, 800–808. https://doi.org/10.1086/386297
526	Foerster, K., Coulson, T., Sheldon, B.C., Pemberton, J.M., Clutton-Brock, T., Kruuk, L.E.B.,
527	2007. Sexually antagonistic genetic variation for fitness in red deer. Nature 447,
528	1107–1110.
529	Franck, N., Lanne, T., Astrand, O., Engvall, J., Lindstrom, T., Ostgren, C.J., Nystrom, F.H.,
530	2012. Cardiovascular risk factors related to the PPARgamma Pro12Ala polymorphism
531	in patients with type 2 diabetes are gender dependent. Blood Press. 21, 122–127.
532	https://doi.org/10.3109/08037051.2011.623349
533	Fry, J.D., 2010. The Genomic Location of Sexually Antagonistic Variation: Some Cautionary
534	Comments. Evolution 64, 1510–1516. https://doi.org/10.1111/j.1558-
535	5646.2009.00898.x
536	Garver-Apgar, C.E., Eaton, M.A., Tybur, J.M., Emery Thompson, M., 2011. Evidence of
537	intralocus sexual conflict: physically and hormonally masculine individuals have more
538	attractive brothers relative to sisters. Evol. Hum. Behav. 32, 423–432.
539	https://doi.org/10.1016/j.evolhumbehav.2011.03.005
540	Gastaldi, M., Diziere, S., Defoort, C., Portugal, H., Lairon, D., Darmon, M., Planells, R., 2007.
541	Sex-specific association of fatty acid binding protein 2 and microsomal triacylglycerol
542	transfer protein variants with response to dietary lipid changes in the 3-mo Medi-
543	RIVAGE primary intervention study. Am. J. Clin. Nutr. 86, 1633–1641.
544	https://doi.org/10.1093/ajcn/86.5.1633
545	Gilks, W.P., Abbott, J.K., Morrow, E.H., 2014. Sex differences in disease genetics: evidence,
546	evolution, and detection. Trends Genet. 30, 453–463.
547	https://doi.org/10.1016/j.tig.2014.08.006
548	Gloria-Bottini, F., Bottini, N., Renzetti, G., Bottini, E., 2007. ACP1 and Th class of
549	immunological disease: evidence of interaction with gender. Int. Arch. Allergy
550	Immunol. 143, 170–176. https://doi.org/10.1159/000099308
551	Grieshop, K., Arnqvist, G., 2018. Sex-specific dominance reversal of genetic variation for
552	fitness. PLOS Biol. 16, e2006810. https://doi.org/10.1371/journal.pbio.2006810
553	Gurevitch, J., Koricheva, J., Mengersen, K., 2013. Handbook of Meta-Analysis In Ecology and
554	Evolution, Handbook of Meta-analysis in Ecology and Evolution.
555	https://doi.org/10.1515/9781400846184
556	Herman, A.I., Conner, T.S., Anton, R.F., Gelernter, J., Kranzler, H.R., Covault, J., 2011.
557	Variation in the gene encoding the serotonin transporter is associated with a
558	measure of sociopathy in alcoholics. Addict. Biol. 16, 124–132.
559	https://doi.org/10.1111/j.1369-1600.2009.00197.x
560	Khramtsova, E.A., Davis, L.K., Stranger, B.E., 2019. The role of sex in the genomics of human
561	complex traits. Nat. Rev. Genet. 20, 173–190. https://doi.org/10.1038/s41576-018-
562	0083-1

563 Kim, B., Kim, H., Joo, Y.H., Lim, J., Kim, C.-Y., Song, K., 2010. Sex-different association of DAO 564 with schizophrenia in Koreans. Psychiatry Res. 179, 121–125. 565 https://doi.org/10.1016/j.psychres.2008.08.009 566 Kiy, A., Wilhelm, O., Hildebrandt, A., Reuter, M., Sommer, W., 2013. On the genetic basis of face cognition and its relation to fluid cognitive abilities. Genes Brain Behav. 12, 438-567 568 445. https://doi.org/10.1111/gbb.12034 569 Korner, A., Ma, L., Franks, P.W., Kiess, W., Baier, L.J., Stumvoll, M., Kovacs, P., 2007. Sexspecific effect of the Val1483Ile polymorphism in the fatty acid synthase gene (FAS) 570 on body mass index and lipid profile in Caucasian children. Int. J. Obes. 2005 31, 571 572 353-358. https://doi.org/10.1038/sj.ijo.0803428 573 Lajeunesse, M., 2013. Recovering missing or partial data from studies: A survey of 574 conversions and imputations for meta-analysis. pp. 195–206. 575 Lande, R., 1980. Sexual dimorphism, sexual selection, and adaptation in polygenic 576 characters. Evolution 34, 292-305. 577 Lang, U.E., Hellweg, R., Bajbouj, M., Gaus, V., Sander, T., Gallinat, J., 2008. Gender-578 dependent association of a functional NGF polymorphism with anxiety-related 579 personality traits. Pharmacopsychiatry 41, 196–199. https://doi.org/10.1055/s-0028-580 1082070 Lauritzen, L., Sorensen, L.B., Harslof, L.B., Ritz, C., Stark, K.D., Astrup, A., Dyssegaard, C.B., 581 582 Egelund, N., Michaelsen, K.F., Damsgaard, C.T., 2017. Mendelian randomization 583 shows sex-specific associations between long-chain. Am. J. Clin. Nutr. 106, 88–95. 584 https://doi.org/10.3945/ajcn.117.152595 Lee, S.K., 2018. Sex as an important biological variable in biomedical research. BMB Rep. 51, 585 586 167-173. https://doi.org/10.5483/BMBRep.2018.51.4.034 587 Liu, Y.-H., Chen, Y.-J., Wu, H.-H., Wang, T.-Y., Tsai, F.-J., 2014. Single nucleotide 588 polymorphisms at the PRR3, ABCF1, and GNL1 genes in the HLA class I region are 589 associated with Graves' ophthalmopathy in a gender-dependent manner. 590 Ophthalmology 121, 2033–2039. https://doi.org/10.1016/j.ophtha.2014.04.027 591 Ljungberg, L.U., Ostgren, C.J., Nystrom, F.H., Lanne, T., 2014. Associations of genetic 592 polymorphisms in the renin-angiotensin system with central aortic and ambulatory 593 blood pressure in type 2 diabetic patients. J. Renin-Angiotensin-Aldosterone Syst. 594 JRAAS 15, 61–68. https://doi.org/10.1177/1470320312474052 595 McCarthy, J.J., Somji, A., Weiss, L.A., Steffy, B., Vega, R., Barrett-Connor, E., Talavera, G., 596 Glynne, R., 2009. Polymorphisms of the scavenger receptor class B member 1 are 597 associated with insulin resistance with evidence of gene by sex interaction. J. Clin. 598 Endocrinol. Metab. 94, 1789–1796. https://doi.org/10.1210/jc.2008-2800 599 Mills, S.C., Koskela, E., Mappes, T., 2011. Intralocus sexual conflict for fitness: sexually 600 antagonistic alleles for testosterone. Proc. R. Soc. B Biol. Sci. rspb20112340. 601 https://doi.org/10.1098/rspb.2011.2340 602 Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Group, T.P., 2009. Preferred Reporting 603 Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLOS 604 Med. 6, e1000097. https://doi.org/10.1371/journal.pmed.1000097 Morea, A., Cameran, M., Rebuffi, A.G., Marzenta, D., Marangon, O., Picci, L., Zacchello, F., 605 Scarpa, M., 2005. Gender-sensitive association of CFTR gene mutations and 5T allele 606 607 emerging from a large survey on infertility. Mol. Hum. Reprod. 11, 607–614. 608 https://doi.org/10.1093/molehr/gah214

- 609 Morrow, E.H., 2015. The evolution of sex differences in disease. Biol. Sex Differ. 6, 5. 610 https://doi.org/10.1186/s13293-015-0023-0 611 Morrow, E.H., Connallon, T., 2013. Implications of sex-specific selection for the genetic basis 612 of disease. Evol. Appl. 6, 1208–1217. https://doi.org/10.1111/eva.12097 613 Nesse, R.M., Williams, G.C., 1994. Why we get sick: The new science of Darwinian medicine. Vintage, New York. 614 615 Ober, C., Loisel, D.A., Gilad, Y., 2008. Sex-specific genetic architecture of human disease. Nat Rev Genet 9, 911–922. https://doi.org/10.1038/nrg2415 616 617 Ober, C., Pan, L., Phillips, N., Parry, R., Kurina, L.M., 2006. Sex-specific genetic architecture of 618 asthma-associated quantitative trait loci in a founder population. Curr. Allergy 619 Asthma Rep. 6, 241–246. https://doi.org/10.1007/s11882-006-0041-4 620 Ovadia, G., Shifman, S., 2011. The genetic variation of RELN expression in schizophrenia and 621 bipolar disorder. PloS One 6, e19955. https://doi.org/10.1371/journal.pone.0019955 622 Padmanabhan, S., Menni, C., Lee, W.K., Laing, S., Brambilla, P., Sega, R., Perego, R., Grassi, 623 G., Cesana, G., Delles, C., Mancia, G., Dominiczak, A.F., 2010. The effects of sex and 624 method of blood pressure measurement on genetic associations with blood pressure 625 in the PAMELA study. J. Hypertens. 28, 465–477. 626 https://doi.org/10.1097/HJH.0b013e32833594d7 627 Parker, G.A., 1979. SEXUAL SELECTION AND SEXUAL CONFLICT, in: Sexual Selection and 628 Reproductive Competition in Insects. Elsevier, pp. 123–166. 629 https://doi.org/10.1016/B978-0-12-108750-0.50010-0 630 Parker, G.A., Baker, R.R., Smith, V.G.F., 1972. The origin and evolution of gamete 631 dimorphism and the male-female phenomenon. J. Theor. Biol. 36, 529–553. 632 Payne, E.H., Gebregziabher, M., Hardin, J.W., Ramakrishnan, V., Egede, L.E., 2018. An 633 empirical approach to determine a threshold for assessing overdispersion in Poisson 634 and negative binomial models for count data. Commun. Stat. Simul. Comput. 47, 635 1722–1738. https://doi.org/10.1080/03610918.2017.1323223 636 Peng, Y.-M., Lei, S.-F., Guo, Y., Xiong, D.-H., Yan, H., Wang, L., Guo, Y.-F., Deng, H.-W., 2008. 637 Sex-specific association of the glucocorticoid receptor gene with extreme BMD. J. 638 Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 23, 247–252. 639 https://doi.org/10.1359/jbmr.071017 640 Pennell, T.M., Haas, F.J.H. de, Morrow, E.H., Doorn, G.S. van, 2016. Contrasting effects of 641 intralocus sexual conflict on sexually antagonistic coevolution. Proc. Natl. Acad. Sci. 642 113, E978–E986. https://doi.org/10.1073/pnas.1514328113 643 Pennell, T.M., Morrow, E.H., 2013. Two sexes, one genome: the evolutionary dynamics of 644 intralocus sexual conflict. Ecol. Evol. 3, 1819–1834. 645 https://doi.org/10.1002/ece3.540 646 Press, O.A., Zhang, W., Gordon, M.A., Yang, D., Haiman, C.A., Azuma, M., Iqbal, S., Lenz, H.-647 J., 2011. Gender-related survival differences associated with polymorphic variants of 648 estrogen receptor-beta (ERbeta) in patients with metastatic colon cancer. 649 Pharmacogenomics J. 11, 375–382. https://doi.org/10.1038/tpj.2010.45 650 Price, J.S., Strong, J., Eliassen, J., McQueeny, T., Miller, M., Padula, C.B., Shear, P., Lisdahl, K., 651 2013. Serotonin transporter gene moderates associations between mood, memory 652 and hippocampal volume. Behav. Brain Res. 242, 158–165. https://doi.org/10.1016/j.bbr.2012.11.013 653 654 Rice, W.R., 1992. Sexually antagonistic genes: experimental evidence. Science 256, 1436-655 1439. https://doi.org/10.1126/science.1604317

656 Rice, W.R., 1984. Sex chromosomes and the evolution of sexual dimorphism. Evolution 38, 657 735-742. 658 Rigby, N., Kulathinal, R.J., 2015. Genetic Architecture of Sexual Dimorphism in Humans. J. 659 Cell. Physiol. 230, 2304–2310. https://doi.org/10.1002/jcp.24979 660 Rostant, W.G., Kay, C., Wedell, N., Hosken, D.J., 2015. Sexual conflict maintains variation at 661 an insecticide resistance locus. BMC Biol. 13. https://doi.org/10.1186/s12915-015-662 0143-3 663 Ruzicka, F., Connallon, T., 2020. Is the X chromosome a hot spot for sexually antagonistic 664 polymorphisms? Biases in current empirical tests of classical theory. Proc. R. Soc. B. https://doi.org/10.1098/rspb.2020.1869 665 Ruzicka, F., Dutoit, L., Czuppon, P., Jordan, C.Y., Li, X.-Y., Olito, C., Runemark, A., Svensson, 666 E.I., Yazdi, H.P., Connallon, T., 2020. The search for sexually antagonistic genes: 667 Practical insights from studies of local adaptation and statistical genomics. Evol. Lett. 668 669 4-5, 398-415. https://doi.org/10.1002/evl3.192 670 Ruzicka, F., Hill, M.S., Pennell, T.M., Flis, I., Ingleby, F.C., Mott, R., Fowler, K., Morrow, E.H., 671 Reuter, M., 2019. Genome-wide sexually antagonistic variants reveal long-standing 672 constraints on sexual dimorphism in fruit flies. PLoS Biol. 17, e3000244. 673 Sainz, J., Rudolph, A., Hoffmeister, M., Frank, B., Brenner, H., Chang-Claude, J., Hemminki, K., Forsti, A., 2012. Effect of type 2 diabetes predisposing genetic variants on 674 675 colorectal cancer risk. J. Clin. Endocrinol. Metab. 97, E845-851. 676 https://doi.org/10.1210/jc.2011-2565 677 Sangalli, A., Orlandi, E., Poli, A., Maurichi, A., Santinami, M., Nicolis, M., Ferronato, S., 678 Malerba, G., Rodolfo, M., Gomez Lira, M., 2017. Sex-specific effect of RNASEL 679 rs486907 and miR-146a rs2910164 polymorphisms' interaction as a susceptibility 680 factor for melanoma skin cancer. Melanoma Res. 27, 309-314. 681 https://doi.org/10.1097/CMR.000000000000360 Schneider, K.K., Hule, L., Schote, A.B., Meyer, J., Frings, C., 2015. Sex matters! Interactions of 682 683 sex and polymorphisms of a cholinergic receptor gene (CHRNA5) modulate response speed. Neuroreport 26, 186–191. https://doi.org/10.1097/WNR.000000000000313 684 685 Schuurhof, A., Bont, L., Siezen, C.L.E., Hodemaekers, H., van Houwelingen, H.C., Kimman, T.G., Hoebee, B., Kimpen, J.L.L., Janssen, R., 2010. Interleukin-9 polymorphism in 686 687 infants with respiratory syncytial virus infection: an opposite effect in boys and girls. 688 Pediatr. Pulmonol. 45, 608–613. https://doi.org/10.1002/ppul.21229 689 Shalev, I., Lerer, E., Israel, S., Uzefovsky, F., Gritsenko, I., Mankuta, D., Ebstein, R.P., Kaitz, 690 M., 2009. BDNF Val66Met polymorphism is associated with HPA axis reactivity to 691 psychological stress characterized by genotype and gender interactions. 692 Psychoneuroendocrinology 34, 382–388. 693 https://doi.org/10.1016/j.psyneuen.2008.09.017 694 Short, R.V., 1979. Sexual selection and its component parts, somatic and genital selection, as 695 illustrated by man and the great apes. Adv. Study Behav. 9, 131–158. 696 Sjoberg, R.L., Nilsson, K.W., Nordquist, N., Ohrvik, J., Leppert, J., Lindstrom, L., Oreland, L., 697 2006. Development of depression: sex and the interaction between environment 698 and a promoter polymorphism of the serotonin transporter gene. Int. J. 699 Neuropsychopharmacol. 9, 443–449. https://doi.org/10.1017/S1461145705005936 700 Stearns, S.C., Govindaraju, D.R., Ewbank, D., Byars, S.G., 2012. Constraints on the 701 coevolution of contemporary human males and females. Proc. R. Soc. B Biol. Sci. 279, 702 4836-4844. https://doi.org/10.1098/rspb.2012.2024

703 Stulp, G., Kuijper, B., Buunk, A.P., Pollet, T.V., Verhulst, S., 2012. Intralocus sexual conflict 704 over human height. Biol. Lett. https://doi.org/10.1098/rsbl.2012.0590 705 Winkler, T.W., Justice, A.E., Graff, M., Barata, L., Feitosa, M.F., Chu, S., Czajkowski, J., Esko, 706 T., Fall, T., Kilpeläinen, T.O., Lu, Y., Mägi, R., Mihailov, E., Pers, T.H., Rüeger, S., 707 Teumer, A., Ehret, G.B., Ferreira, T., Heard-Costa, N.L., Karjalainen, J., Lagou, V., 708 Mahajan, A., Neinast, M.D., Prokopenko, I., Simino, J., Teslovich, T.M., Jansen, R., 709 Westra, H.-J., White, C.C., Absher, D., Ahluwalia, T.S., Ahmad, S., Albrecht, E., Alves, 710 A.C., Bragg-Gresham, J.L., Craen, A.J.M. de, Bis, J.C., Bonnefond, A., Boucher, G., 711 Cadby, G., Cheng, Y.-C., Chiang, C.W.K., Delgado, G., Demirkan, A., Dueker, N., 712 Eklund, N., Eiriksdottir, G., Eriksson, J., Feenstra, B., Fischer, K., Frau, F., Galesloot, 713 T.E., Geller, F., Goel, A., Gorski, M., Grammer, T.B., Gustafsson, S., Haitjema, S., 714 Hottenga, J.-J., Huffman, J.E., Jackson, A.U., Jacobs, K.B., Johansson, Å., Kaakinen, M., 715 Kleber, M.E., Lahti, J., Leach, I.M., Lehne, B., Liu, Y., Lo, K.S., Lorentzon, M., Luan, J., 716 Madden, P.A.F., Mangino, M., McKnight, B., Medina-Gomez, C., Monda, K.L., 717 Montasser, M.E., Müller, G., Müller-Nurasyid, M., Nolte, I.M., Panoutsopoulou, K., 718 Pascoe, L., Paternoster, L., Rayner, N.W., Renström, F., Rizzi, F., Rose, L.M., Ryan, 719 K.A., Salo, P., Sanna, S., Scharnagl, H., Shi, J., Smith, A.V., Southam, L., Stančáková, A., 720 Steinthorsdottir, V., Strawbridge, R.J., Sung, Y.J., Tachmazidou, I., Tanaka, T., 721 Thorleifsson, G., Trompet, S., Pervjakova, N., Tyrer, J.P., Vandenput, L., Laan, S.W. 722 van der, Velde, N. van der, Setten, J. van, Vliet-Ostaptchouk, J.V. van, Verweij, N., 723 Vlachopoulou, E., Waite, L.L., Wang, S.R., Wang, Z., Wild, S.H., Willenborg, C., Wilson, 724 J.F., Wong, A., Yang, J., Yengo, L., Yerges-Armstrong, L.M., Yu, L., Zhang, W., Zhao, 725 J.H., Andersson, E.A., Bakker, S.J.L., Baldassarre, D., Banasik, K., Barcella, M., 726 Barlassina, C., Bellis, C., Benaglio, P., Blangero, J., Blüher, M., Bonnet, F., 727 Bonnycastle, L.L., Boyd, H.A., Bruinenberg, M., Buchman, A.S., Campbell, H., Chen, 728 Y.-D.I., Chines, P.S., Claudi-Boehm, S., Cole, J., Collins, F.S., Geus, E.J.C. de, Groot, 729 L.C.P.G.M. de, Dimitriou, M., Duan, J., Enroth, S., Eury, E., Farmaki, A.-E., Forouhi, 730 N.G., Friedrich, N., Gejman, P.V., Gigante, B., Glorioso, N., Go, A.S., Gottesman, O., 731 Gräßler, J., Grallert, H., Grarup, N., Gu, Y.-M., Broer, L., Ham, A.C., Hansen, T., Harris, 732 T.B., Hartman, C.A., Hassinen, M., Hastie, N., Hattersley, A.T., Heath, A.C., Henders, 733 A.K., Hernandez, D., Hillege, H., Holmen, O., Hovingh, K.G., Hui, J., Husemoen, L.L., 734 Hutri-Kähönen, N., Hysi, P.G., Illig, T., Jager, P.L.D., Jalilzadeh, S., Jørgensen, T., 735 Jukema, J.W., Juonala, M., Kanoni, S., Karaleftheri, M., Khaw, K.T., Kinnunen, L., 736 Kittner, S.J., Koenig, W., Kolcic, I., Kovacs, P., Krarup, N.T., Kratzer, W., Krüger, J., 737 Kuh, D., Kumari, M., Kyriakou, T., Langenberg, C., Lannfelt, L., Lanzani, C., Lotay, V., 738 Launer, L.J., Leander, K., Lindström, J., Linneberg, A., Liu, Y.-P., Lobbens, S., Luben, R., 739 Lyssenko, V., Männistö, S., Magnusson, P.K., McArdle, W.L., Menni, C., Merger, S., 740 Milani, L., Montgomery, G.W., Morris, A.P., Narisu, N., Nelis, M., Ong, K.K., Palotie, 741 A., Pérusse, L., Pichler, I., Pilia, M.G., Pouta, A., Rheinberger, M., Ribel-Madsen, R., Richards, M., Rice, K.M., Rice, T.K., Rivolta, C., Salomaa, V., Sanders, A.R., Sarzynski, 742 743 M.A., Scholtens, S., Scott, R.A., Scott, W.R., Sebert, S., Sengupta, S., Sennblad, B., 744 Seufferlein, T., Silveira, A., Slagboom, P.E., Smit, J.H., Sparsø, T.H., Stirrups, K., Stolk, 745 R.P., Stringham, H.M., Swertz, M.A., Swift, A.J., Syvänen, A.-C., Tan, S.-T., Thorand, 746 B., Tönjes, A., Tremblay, A., Tsafantakis, E., Most, P.J. van der, Völker, U., Vohl, M.-C., 747 Vonk, J.M., Waldenberger, M., Walker, R.W., Wennauer, R., Widén, E., Willemsen, 748 G., Wilsgaard, T., Wright, A.F., Zillikens, M.C., Dijk, S.C. van, Schoor, N.M. van, 749 Asselbergs, F.W., Bakker, P.I.W. de, Beckmann, J.S., Beilby, J., Bennett, D.A.,

750	
750	Bergman, R.N., Bergmann, S., Böger, C.A., Boehm, B.O., Boerwinkle, E., Boomsma,
751	D.I., Bornstein, S.R., Bottinger, E.P., Bouchard, C., Chambers, J.C., Chanock, S.J.,
752	Chasman, D.I., Cucca, F., Cusi, D., Dedoussis, G., Erdmann, J., Eriksson, J.G., Evans,
753	D.A., Faire, U. de, Farrall, M., Ferrucci, L., Ford, I., Franke, L., Franks, P.W., Froguel, P.,
754	Gansevoort, R.T., Gieger, C., Grönberg, H., Gudnason, V., Gyllensten, U., Hall, P.,
755	Hamsten, A., Harst, P. van der, Hayward, C., Heliövaara, M., Hengstenberg, C., Hicks,
756	A.A., Hingorani, A., Hofman, A., Hu, F., Huikuri, H.V., Hveem, K., James, A.L., Jordan,
757	J.M., Jula, A., Kähönen, M., Kajantie, E., Kathiresan, S., Kiemeney, L.A.L.M., Kivimaki,
758	M., Knekt, P.B., Koistinen, H.A., Kooner, J.S., Koskinen, S., Kuusisto, J., Maerz, W.,
759	Martin, N.G., Laakso, M., Lakka, T.A., Lehtimäki, T., Lettre, G., Levinson, D.F., Lind, L.,
760	Lokki, ML., Mäntyselkä, P., Melbye, M., Metspalu, A., Mitchell, B.D., Moll, F.L.,
761	Murray, J.C., Musk, A.W., Nieminen, M.S., Njølstad, I., Ohlsson, C., Oldehinkel, A.J.,
762	Oostra, B.A., Palmer, L.J., Pankow, J.S., Pasterkamp, G., Pedersen, N.L., Pedersen, O.,
763	Penninx, B.W., Perola, M., Peters, A., Polašek, O., Pramstaller, P.P., Psaty, B.M., Qi,
764	L., Quertermous, T., Raitakari, O.T., Rankinen, T., Rauramaa, R., Ridker, P.M., Rioux,
765	J.D., Rivadeneira, F., Rotter, J.I., Rudan, I., Ruijter, H.M. den, Saltevo, J., Sattar, N.,
766	Schunkert, H., Schwarz, P.E.H., Shuldiner, A.R., Sinisalo, J., Snieder, H., Sørensen,
767	T.I.A., Spector, T.D., Staessen, J.A., Stefania, B., Thorsteinsdottir, U., Stumvoll, M.,
768	Tardif, JC., Tremoli, E., Tuomilehto, J., Uitterlinden, A.G., Uusitupa, M., Verbeek,
769	A.L.M., Vermeulen, S.H., Viikari, J.S., Vitart, V., Völzke, H., Vollenweider, P., Waeber,
770	G., Walker, M., Wallaschofski, H., Wareham, N.J., Watkins, H., Zeggini, E.,
771	Consortium, C., Consortium, D., Consortium, G., Consortium, GBpg., Consortium, I.,
772	Consortium, M., Chakravarti, A., Clegg, D.J., Cupples, L.A., Gordon-Larsen, P., Jaquish,
773	C.E., Rao, D.C., Abecasis, G.R., Assimes, T.L., Barroso, I., Berndt, S.I., Boehnke, M.,
774	Deloukas, P., Fox, C.S., Groop, L.C., Hunter, D.J., Ingelsson, E., Kaplan, R.C., McCarthy,
775	M.I., Mohlke, K.L., O'Connell, J.R., Schlessinger, D., Strachan, D.P., Stefansson, K.,
776	Duijn, C.M. van, Hirschhorn, J.N., Lindgren, C.M., Heid, I.M., North, K.E., Borecki, I.B.,
777	Kutalik, Z., Loos, R.J.F., 2015. The Influence of Age and Sex on Genetic Associations
778	with Adult Body Size and Shape: A Large-Scale Genome-Wide Interaction Study.
779	PLOS Genet. 11, e1005378. https://doi.org/10.1371/journal.pgen.1005378
780	Wise, A.L., Gyi, L., Manolio, T.A., 2013. eXclusion: Toward Integrating the X Chromosome in
781	Genome-wide Association Analyses. Am. J. Hum. Genet. 92, 643–647.
782	https://doi.org/10.1016/j.ajhg.2013.03.017
783	Wong, S.Y.S., Lau, E.M.C., Li, M., Chung, T., Sham, A., Woo, J., 2005. The prevalence of Apo
784	E4 genotype and its relationship to bone mineral density in Hong Kong Chinese. J.
785	Bone Miner. Metab. 23, 261–265. https://doi.org/10.1007/s00774-004-0593-0
786	Wu, K., Chen, C., Moyzis, R.K., Greenberger, E., Yu, Z., 2016. Gender Interacts with Opioid
787	Receptor Polymorphism A118G and Serotonin Receptor Polymorphism -1438 A/G on
788	Speed-Dating Success. Hum. Nat. Hawthorne N 27, 244–260.
789	https://doi.org/10.1007/s12110-016-9257-8
790	Youssef, S.S., Abd El Aal, A.M., Nasr, A.S., el Zanaty, T., Seif, S.M., 2013. Interleukin-12B gene
791	polymorphism frequencies in Egyptians and sex-related susceptibility to hepatitis C
791	infection. J. Interferon Cytokine Res. Off. J. Int. Soc. Interferon Cytokine Res. 33, 415–
792 793	419. https://doi.org/10.1089/jir.2012.0161
193	413. https://uoi.org/10.1003/jii.2012.0101

medRxiv preprint doi: https://doi.org/10.1101/2020.12.16.20248300; this version posted February 12, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Supplementary Material 794

795

797

796 Both stages of the PubMed literature search employed a Species filter set to Humans only.

798 Stage 1 Search term:

- 800 antagonism[Title/Abstract] AND loci[Title/Abstract])) OR (sexual antagonism[Title/Abstract]
- AND gene[Title/Abstract])) OR (sexual antagonism[Title/Abstract] AND snp[Title/Abstract])) 801
- 802 OR (sexual antagonism[Title/Abstract] AND polymorphism[Title/Abstract])) OR (sexual
- 803 antagonism[Title/Abstract] AND variant[Title/Abstract])) OR (sexual
- 804 antagonism[Title/Abstract] AND allele[Title/Abstract])) OR (sexually
- 805 antagonistic[Title/Abstract] AND locus[Title/Abstract])) OR (sexually
- 806 antagonistic[Title/Abstract] AND loci[Title/Abstract])) OR (sexually
- 807 antagonistic[Title/Abstract] AND gene[Title/Abstract])) OR (sexually
- 808 antagonistic[Title/Abstract] AND snp[Title/Abstract])) OR (sexually
- 809 antagonistic[Title/Abstract] AND polymorphism[Title/Abstract])) OR (sexually
- 810 antagonistic[Title/Abstract] AND variant[Title/Abstract])) OR (sexually
- 811 antagonistic[Title/Abstract] AND allele[Title/Abstract])) OR (intralocus sexual
- 812 conflict[Title/Abstract] AND locus[Title/Abstract])) OR (intralocus sexual
- 813 conflict[Title/Abstract] AND loci[Title/Abstract])) OR (intralocus sexual
- 814 conflict[Title/Abstract] AND gene[Title/Abstract])) OR (intralocus sexual
- 815 conflict[Title/Abstract] AND snp[Title/Abstract])) OR (intralocus sexual
- 816 conflict[Title/Abstract] AND polymorphism[Title/Abstract])) OR (intralocus sexual
- 817 conflict[Title/Abstract] AND variant[Title/Abstract])) OR (intralocus sexual
- 818 conflict[Title/Abstract] AND allele[Title/Abstract])
- 819
- 820
- 821
- 822 Stage 2 Search term:
- 823
- 824 opposite[Title/Abstract] AND locus[Title/Abstract]) OR (gender[Title/Abstract] AND
- 825 opposite[Title/Abstract] AND loci[Title/Abstract])) OR (gender[Title/Abstract] AND
- 826 opposite[Title/Abstract] AND gene[Title/Abstract])) OR (gender[Title/Abstract] AND
- 827 opposite[Title/Abstract] AND snp[Title/Abstract])) OR (gender[Title/Abstract] AND
- 828 opposite[Title/Abstract] AND polymorphism[Title/Abstract])) OR (gender[Title/Abstract]
- 829 AND opposite[Title/Abstract] AND variant[Title/Abstract])) OR (sex[Title/Abstract] AND
- 830 opposite[Title/Abstract] AND locus[Title/Abstract])) OR (sex[Title/Abstract] AND
- opposite[Title/Abstract] AND loci[Title/Abstract])) OR (sex[Title/Abstract] AND 831
- 832 opposite[Title/Abstract] AND gene[Title/Abstract])) OR (sex[Title/Abstract] AND
- 833 opposite[Title/Abstract] AND snp[Title/Abstract])) OR (sex[Title/Abstract] AND
- 834 opposite[Title/Abstract] AND polymorphism[Title/Abstract])) OR (sex[Title/Abstract] AND
- 835 opposite[Title/Abstract] AND variant[Title/Abstract])) OR (sex dependent[Title/Abstract]
- 836 AND locus[Title/Abstract])) OR (sex dependent[Title/Abstract] AND loci[Title/Abstract])) OR
- 837 (sex dependent[Title/Abstract] AND gene[Title/Abstract])) OR (sex
- 838 dependent[Title/Abstract] AND snp[Title/Abstract])) OR (sex dependent[Title/Abstract] AND
- 839 polymorphism[Title/Abstract])) OR (sex dependent[Title/Abstract] AND
- 840 variant[Title/Abstract])) OR (sex different[Title/Abstract] AND locus[Title/Abstract])) OR (sex

different[Title/Abstract] AND loci[Title/Abstract])) OR (sex different[Title/Abstract] AND 841 842 gene[Title/Abstract])) OR (sex different[Title/Abstract] AND snp[Title/Abstract])) OR (sex 843 different[Title/Abstract] AND polymorphism[Title/Abstract])) OR (sex 844 different[Title/Abstract] AND variant[Title/Abstract])) OR (gender-dependent[Title/Abstract] 845 AND locus[Title/Abstract])) OR (gender-dependent[Title/Abstract] AND loci[Title/Abstract])) 846 OR (gender-dependent[Title/Abstract] AND gene[Title/Abstract])) OR (gender-847 dependent[Title/Abstract] AND snp[Title/Abstract])) OR (gender-dependent[Title/Abstract] AND polymorphism[Title/Abstract])) OR (gender-dependent[Title/Abstract] AND 848 849 variant[Title/Abstract])) OR (male[Title/Abstract] AND female[Title/Abstract] AND 850 opposite[Title/Abstract] AND locus[Title/Abstract])) OR (male[Title/Abstract] AND 851 female[Title/Abstract] AND opposite[Title/Abstract] AND loci[Title/Abstract])) OR 852 (male[Title/Abstract] AND female[Title/Abstract] AND opposite[Title/Abstract] AND 853 gene[Title/Abstract])) OR (male[Title/Abstract] AND female[Title/Abstract] AND 854 opposite[Title/Abstract] AND snp[Title/Abstract])) OR (male[Title/Abstract] AND 855 female[Title/Abstract] AND opposite[Title/Abstract] AND polymorphism[Title/Abstract])) OR 856 (male[Title/Abstract] AND female[Title/Abstract] AND opposite[Title/Abstract] AND variant[Title/Abstract])) OR (men[Title/Abstract] AND women[Title/Abstract] AND 857 858 opposite[Title/Abstract] AND locus[Title/Abstract])) OR (men[Title/Abstract] AND 859 women[Title/Abstract] AND opposite[Title/Abstract] AND loci[Title/Abstract])) OR 860 (men[Title/Abstract] AND women[Title/Abstract] AND opposite[Title/Abstract] AND gene[Title/Abstract])) OR (men[Title/Abstract] AND women[Title/Abstract] AND 861 862 opposite[Title/Abstract] AND snp[Title/Abstract])) OR (men[Title/Abstract] AND women[Title/Abstract] AND opposite[Title/Abstract] AND polymorphism[Title/Abstract])) 863 864 OR (men[Title/Abstract] AND women[Title/Abstract] AND opposite[Title/Abstract] AND 865 variant[Title/Abstract])) OR (boys[Title/Abstract] AND girls[Title/Abstract] AND 866 opposite[Title/Abstract] AND locus[Title/Abstract])) OR (boys[Title/Abstract] AND 867 girls[Title/Abstract] AND opposite[Title/Abstract] AND loci[Title/Abstract])) OR 868 (boys[Title/Abstract] AND girls[Title/Abstract] AND opposite[Title/Abstract] AND gene[Title/Abstract])) OR (boys[Title/Abstract] AND girls[Title/Abstract] AND 869 870 opposite[Title/Abstract] AND snp[Title/Abstract])) OR (boys[Title/Abstract] AND 871 girls[Title/Abstract] AND opposite[Title/Abstract] AND polymorphism[Title/Abstract])) OR 872 (boys[Title/Abstract] AND girls[Title/Abstract] AND opposite[Title/Abstract] AND 873 variant[Title/Abstract])) OR (gender[Title/Abstract] AND opposite[Title/Abstract] AND 874 allele[Title/Abstract])) OR (sex[Title/Abstract] AND opposite[Title/Abstract] AND 875 allele[Title/Abstract])) OR (sex dependent[Title/Abstract] AND allele[Title/Abstract])) OR 876 (sex different[Title/Abstract] AND allele[Title/Abstract])) OR (gender-877 dependent[Title/Abstract] AND allele[Title/Abstract])) OR (male[Title/Abstract] AND 878 female[Title/Abstract] AND opposite[Title/Abstract] AND allele[Title/Abstract])) OR 879 (men[Title/Abstract] AND women[Title/Abstract] AND opposite[Title/Abstract] AND 880 allele[Title/Abstract])) OR (boys[Title/Abstract] AND girls[Title/Abstract] AND 881 opposite[Title/Abstract] AND allele[Title/Abstract]) 882 883 884 885







890 Figure S1. Study reported effect allele frequencies and database allele frequencies are strongly correlated. The correlation between reported effect allele frequency and 891 frequencies for the same alleles obtained from the 1000 genomes database (0.94). Filled 892 893 circles represent disease risk/severity related variants while open circles represent complex 894 trait variants.



897

Figure S2. Relationship between study sample size and average extracted effect size

across all studies.





Figure S3. Female effect size and male effect size are negatively correlated in SA alleles. 902

903 Effect size (Cohen's D) of variants in females against effect size in males. Triangular points 904 represent sex-opposite complex trait variants, circular points represent disease risk/severity 905 variants.



909

Figure S4. The relationship between effect allele frequency and effect size ratio, grouped 910

by trait class. Points to the right of the vertical dotted line have a greater negative effect than 911

912 positive. A. Disease risk/severity variants. B. Complex traits. Point size is based on the variance

913 of the effect size ratio, with smaller variance having larger point sizes and greater weighting 914 in the statistical model.